{"preliminary_commentary":{"by_channel":{"youtube":6,"podcast":6,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05118789\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ARROS-1","nct_id":"NCT05118789","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=arros-1-nct05118789. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Zidesamtinib (NVL-520) oral daily dosing","label":"Phase 1 dose escalation","type":"EXPERIMENTAL"},{"description":"ROS1+ NSCLC naïve to TKI therapy and up to 1 prior chemotherapy and/or immunotherapy","label":"Cohort 2a","type":"EXPERIMENTAL"},{"description":"ROS1+ NSCLC treated with 1 prior ROS1 TKI and no prior chemotherapy or immunotherapy","label":"Cohort 2b","type":"EXPERIMENTAL"},{"description":"ROS1+ NSCLC treated with 1 prior ROS1 TKI and 1 prior platinum-based chemotherapy with or without immunotherapy","label":"Cohort 2c","type":"EXPERIMENTAL"},{"description":"ROS1+ NSCLC treated with ≥2 prior ROS1 TKIs and up to 1 prior chemotherapy and/or immunotherapy","label":"Cohort 2d","type":"EXPERIMENTAL"},{"description":"ROS1+ solid tumor and progressed on any prior therapy","label":"Cohort 2e","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"enrollment":{"count":359,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Zidesamtinib (NVL-520)","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"Nuvalent Inc.","official_title":"A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose (MTD) (Phase 1)","timeFrame":"Within 28 days of last patient dosed during dose escalation"},{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"Within 28 days of last patient dosed during dose escalation."},{"measure":"Objective Response Rate (ORR) (Phase 2)","timeFrame":"2-3 years after first patient dosed."}],"references":[],"start_date":{"date":"2022-01-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","url":"https://clinicaltrials.gov/study/NCT05118789"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/arros-1-nct05118789"}